Guynn I, Simon J, Anderson S, Klaman SL, Mullenix A, Cilenti D, Hassmiller Lich K. Tools for supporting the MCH Workforce in addressing complex challenges: a scoping review of system dynamics modeling in maternal and child health. Matern Child Health J. 2022 Aug;26(Suppl 1):S176-203. doi: 10.1007/s10995-022-03376-8
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Williams VSL, Soliman AM, Barrett AM, Klein KO. Review and evaluation of patient-centered psychosocial assessments for children with central precocious puberty or early puberty. J Pediatr Endocrinol Metab. 2018 Apr 25;31(5):485-95.
Lynch MM, Squiers LB, Kosa KM, Dolina S, Read JG, Broussard CS, Frey MT, Polen KN, Lind JN, Gilboa SM, Biermann J. Making decisions about medication use during pregnancy: implications for communication strategies. Matern Child Health J. 2018 Jan;22(1):92-100. doi: 10.1007/s10995-017-2358-0
Wilkinson A, Anderson S, Wheeler SB. Screening for and treating postpartum depression and psychosis: a cost-effectiveness analysis. Matern Child Health J. 2017 Apr;21(4):903-14. doi: 10.1007/s10995-016-2192-9
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Hillemeier MM, Domino ME, Wells R, Goyal RK, Kum HC, Cilenti D, Timothy Whitmire J, Basu A. Effects of maternity care coordination on pregnancy outcomes: propensity-weighted analyses. Matern Child Health J. 2015 Jan;19(1):121-7. doi: 10.1007/s10995-014-1502-3
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Nguyen USDT, Rothman KJ, Demissie S, Jackson DJ, Lang JM, Ecker JL. Epidural analgesia and risks of cesarean and operative vaginal deliveries in nulliparous and multiparous women. Matern Child Health J. 2010 Sep 1;14(5):705-12.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
French M, Neighbors D, Carswell L, Williams R, Bush L. A model for estimating industry compliance costs of food labeling regulations. Agribusiness: An International Journal. 1993;8(2):165-86.